Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).
Priyanka SharmaBruce F KimlerAnne O'DeaLauren NyeYen Y WangRachel YoderJoshua M StaleyLindsey ProchaskaJamie WagnerAmanda L AminKelsey E LarsonChrista R BalanoffManana EliaGregory CraneSheshadri MadhusudhanaMarc HoffmannMaureen SheehanRoberto RodriguezKarissa FinkeRajvi ShahDeepti SatelliAnuj ShresthaLarry BeckRichard McKittrickRobert PluennekeVinay RajaVenkatadri BeekiLarry CorumJaimie HeldstabStephanie LaFaverMicki PragerMilind PhadnisDinesh Pal MudaranthakamRoy A JensenAndrew K GodwinRoberto SalgadoKathan MehtaQamar KhanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The two-drug CbD regimen yielded pCR, RCB 0+I, and survival rates similar to the four-drug regimen of CbP → AC, but with a more favorable toxicity profile and lower treatment-associated cost.